Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab

Abstract The molecular basis of interleukin (IL)‐17A in driving psoriasis pathogenesis is not fully elucidated yet. To investigate the underlying mechanisms and biomarkers associated with IL‐17A and the role in psoriasis pathogenesis, over 30 serum proteins were evaluated in a study assessing the effectiveness and safety of secukinumab, where treatment was directly switched from cyclosporin A to secukinumab. Serum β‐defensin 2 (BD‐2) levels rapidly and robustly reduced following secukinumab treatment. BD‐2 levels were well‐correlated with Psoriasis Area and Severity Index (PASI) score; changes in BD‐2 levels preceded change in PASI score. Serum BD‐2, an easily measurable protein, can possibly be used as a suitable surrogate biomarker to monitor responses to IL‐17A‐targeted therapies for psoriasis in clinical practice.